Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients With Advanced or Unresectable Urothelial Carcinoma of the Bladder
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 24 Nov 2017
At a glance
- Drugs Eribulin (Primary) ; Gemcitabine (Primary)
- Indications Bladder cancer; Urethral cancer
- Focus Therapeutic Use
- 04 Apr 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
- 04 Apr 2017 Status changed from recruiting to active, no longer recruiting.
- 22 Dec 2016 Status changed from active, no longer recruiting to recruiting.